**Supplemental Methods**

## ***Exclusion Criteria***

Key exclusion criteria included presence of ocular hypertension in the study eye at qualification, defined as >23 mmHg without treatment or >21 mmHg if currently taking one intraocular pressure (IOP)-lowering medication; history of corticosteroid-induced IOP increase of >10 mmHg in either eye; or use of intraocular steroid injection or implant within 6 months, treatment with anti-vascular endothelial growth factor (VEGF) within 2 months prior to screening, or any prior treatment with fluocinolone acetonide implant or pan-retinal photocoagulation

Additional exclusion criteria included presence of a clinically significant epiretinal membrane, active retinal or optic disc neovascularization, active or history of choroidal neovascularization, or presence of rubeosis iridis; history or presence of herpetic infection, toxoplasmosis, or chorioretinopathy; moderate non-proliferative diabetic retinopathy or worse in either eye; active infection; aphakia, significant posterior capsule tear or iris trauma in the study eye; anterior-chamber intraocular lens; clinically significant media opacity; history of glaucoma; progressive optic nerve disease or retinal disease other than retinopathy due to RVO that affects BCVA; and any ocular condition in the study eye that, in the opinion of the investigator, would prevent a 15-letter improvement in visual acuity (such as severe macular ischemia). Patients who received the following ophthalmic therapies were also excluded: intraocular surgery (including laser therapy), corneal refractive surgery, or eyelid surgery within 3 months prior to screening or anticipated need for ocular surgery in the study eye during the study; topical corticosteroids in the vicinity of the eyes within 1 month prior to screening; periocular depot of steroids placed within 6 months prior to treatment; and any prohibited ocular medications. Other exclusion criteria included use or anticipated use of systemic corticosteroids during the study; clinically significant or uncontrolled serious or severe medical or psychiatric condition; participation in any other interventional clinical trials within 30 days prior to screening; history of hypersensitivity or poor tolerance to any components of the study drug; and any systemic condition that in the investigator’s opinion might confound the study results.